Prolonged periods between diagnosis and ablation in atrial fibrillation (AF) patients led to increased risk of atrial arrhythmia recurrence at 1 year, according to a new clinical practice registry of patients undergoing radiofrequency ablation (RFA). 

Telehealth, remote blood pressure (BP) monitoring and team-based care can help close the gap in uncontrolled hypertension between rural and urban Americans, a new scientific statement from the American Heart Association (AHA) suggests. 

Optimizing Femoral Closure with ANGIO-SEAL® VIP Vascular Closure Device

Around one fifth of phenotypically “mild” hypertrophic cardiomyopathy (HCM) patients develop major adverse cardiovascular events (MACE) in 7 years, with older age, symptomatic development and steeper remodeling trajectories among the biggest risk factors, according to a new study of the Sarcomeric Human Cardiomyopathy Registry (SHaRe). 

Pentaspline pulsed field ablation (PFA) for atrial fibrillation (AF) is associated with a low rate of procedure- and device-related complications, with no esophageal injury, persistent phrenic nerve injury or pulmonary vein stenosis observed, according to a large real-world U.S. registry. 

GLP-1 receptor agonists were associated with lower rates of death and limb complications in people with both peripheral artery disease (PAD) and type 2 diabetes, according to a new analysis. 

Small mitral valve orifice area should not automatically rule out mitral valve transcatheter edge-to-edge repair (M-TEER) with the PASCAL system, new findings from the REPAIR study suggest.  

An ultra-thin biodegradable polymer (BP) sirolimus-eluting stent (SES) can be used as safely and effectively as a durable polymer (DP) everolimus-eluting stent (EES) in patients who have diabetes plus multivessel disease who undergo percutaneous coronary intervention (PCI), results from the TUXEDO-2 trial show. 

Aspirin's long-standing role in atherosclerotic cardiovascular disease (ASCVD) is narrowing, and shorter courses of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy offer a bleeding-sparing option for selected patients after percutaneous coronary intervention (PCI), according to a new scientific statement from the American College of Cardiology (ACC).